Hormone und Herz – spannende Fälle aus dem klinischen Alltag

Herz und Endokrinium sind eng miteinander verbunden: So ist das Herz nicht nur Synthese- und Wirkort kardialer Hormone, sondern auch Effektororgan peripherer hormonproduzierender Organe. Endokrine Dysbalancen können sich primär kardial manifestieren. Anhand von Fallbeispielen zeigen wir, wie wichtig deren Kenntnis und differenzialdiagnostische Einbeziehung bei kardialen Erkrankungen im interdisziplinären Management ist.

Abstract

The heart is closely connected with the endocrine system. On the one hand, the heart is an endocrine organ itself and produces several hormones like atrial and brain natriuretic peptides. On the other hand, cardiac structures are targets of many hormones like catecholamines, thyroid hormones, and corticosteroids. Therefore, many endocrine diseases come with cardiac symptoms. In this article, we describe three instructive clinical cases of patients with hormonal disorders that mimicked cardiovascular disease. Furthermore, we shortly discuss useful diagnostic and treatment algorithms. All cases emphasize the value of interdisciplinary management of patients with cardiac symptoms.

Schlüsselwörter

Phäochromozytom - Morbus Basedow - Hypoparathyreoidismus - Herzinsuffizienz - kardiovaskuläre Endokrinologie

Key words

pheochromocytoma - Graves' disease - hypoparathyroidism - heart failure - cardiovascular endocrinology

Publication History

Article published online:
01 March 2021

• Literatur

• 1 Ogawa T, de Bold AJ. The heart as an endocrine organ. Endocr Connect 2014; 3: R31-R44 . doi:10.1530/ec-14-0012
• 2 Lei L, Mao Y. Hormone treatments in congestive heart failure. J Int Med Res 2018; 46: 2063-2081 . doi:10.1177/0300060518761262
• 3 Clarke BL, Brown EM, Collins MT. et al Epidemiology and Diagnosis of Hypoparathyroidism. J Clin Endocrinol Metab 2016; 101: 2284-2299 . doi:10.1210/jc.2015-3908
• 4 Bilezikian JP. Hypoparathyroidism. J Clin Endocrinol Metab 2020; 105: 1722-1736 . doi:10.1210/clinem/dgaa113
• 5 Mitchell DM, Regan S, Cooley MR. et al Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 2012; 97: 4507-4514 . doi:10.1210/jc.2012-1808
• 6 Underbjerg L, Sikjaer T, Mosekilde L. et al Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res 2013; 28: 2277-2285 . doi:10.1002/jbmr.1979
• 7 Arlt W, Fremerey C, Callies F. et al Well-being, mood and Calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with Calcium and vitamin D. Eur J Endocrinol 2002; 146: 215-222 . doi:10.1530/eje.0.1460215
• 8 Monego G, Arena V, Pasquini S. et al Ischemic injury activates PTHrP and PTH1R expression in human ventricular cardiomyocytes. Basic Res Cardiol 2009; 104: 427-434 . doi:10.1007/s00395-008-0774-4
• 9 Näbauer M, Callewaert G, Cleemann L. et al Regulation of Calcium release is gated by Calcium current, not gating charge, in cardiac myocytes. Science 1989; 244: 800-803 . doi:10.1126/science.2543067
• 10 Solzbach U, Kitterer HR, Haas H. Reversible congestive heart failure in severe hypocalcemia. Herz 2010; 35: 507-510 . doi:10.1007/s00059-010-3374-7
• 11 Avsar A, Dogan A, Tavli T. A rare cause of reversible dilated cardiomyopathy: hypocalcemia. Echocardiography 2004; 21: 609-612 . doi:10.1111/j.0742-2822.2004.03149.x
• 12 Kazmi AS, Wall BM. Reversible congestive heart failure related to profound hypocalcemia secondary to hypoparathyroidism. Am J Med Sci 2007; 333: 226-229 . doi:10.1097/MAJ.0b013e318039b9c6
• 13 De Leo S, Lee SY, Braverman LE. Hyperthyroidism. The Lancet 2016; 388: 906-918 . doi:10.1016/S0140-6736(16)00278-6
• 14 Abdel-Moneim A, Gaber AM, Gouda S. et al Relationship of thyroid dysfunction with cardiovascular diseases: updated review on heart failure progression. Hormones (Athens) 2020; 19: 301-309 . doi:10.1007/s42000-020-00208-8
• 15 Fazio S, Palmieri EA, Lombardi G. et al Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 2004; 59: 31-50 . doi:10.1210/rp.59.1.31
• 16 Geroula A, Deutschbein T, Langton K. et al Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. Eur J Endocrinol 2019; 181: 409-420 . doi:10.1530/eje-19-0159
• 17 Eisenhofer G, Prejbisz A, Peitzsch M. et al Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clin Chem 2018; 64: 1646-1656 . doi:10.1373/clinchem.2018.291369
• 18 Lenders JWM, Kerstens MN, Amar L. et al Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the ESH. J Hypertens 2020; 38: 1443-1456 . doi:10.1097/hjh.0000000000002438
• 19 Plouin PF, Amar L, Dekkers OM. et al European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol 2016; 174: G1-G10 . doi:10.1530/eje-16-0033
• 20 Fassnacht M, Assie G, Baudin E. et al Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 1476-1490 . doi:10.1016/j.annonc.2020.08.2099